Latest news and research on all cancers and treatments, updated several times a week, plus 10,000-item data base of these
Cancer immunotherapy is characterized by the use of the body's own immune system to help fight cancer. One immunotherapy strategy is based on ...
Promising Outcomes Reported For a Personalized Vaccine Against Cutaneous Melanoma - Melanoma News Today
The cancer cells are able to hide from the immune system in part by suppressing the white blood cells that would normally attack them.
The immune system is highly tolerant of cancer because, unlike infection, cancer arises from the body's own healthy tissue. Only in the last 50 years ...
Suspecting that the immune system played a role in this mysterious response, he tried treating cancer patients with bacteria in an effort to turn on the ...
INO-3112, an active immunotherapy that targets HPV 16 and 18 and ... in cancer patients after treatment with an Inovio DNA immunotherapy.
Inovio Pharmaceuticals' HPV Immunotherapy Recognized as "Best Therapeutic Vaccine" by World ... -GlobeNewswire (press release)
Mr. Goldman will be speaking as part of the co-located Cancer & Immunotherapy conference. The Company's presentation will take place on Thursday ...
They have been used in cancer immunotherapies to target several different kinds of tumors. The process relies on extracting dendritic cells from ...
Rates for response and clinical benefit to immunotherapy served as the ... When researchers stratified the analysis according to type of immunotherapy, ... can be reached at Vanderbilt-Ingram Cancer Center, 691 Preston Building, ...
“We are excited to present the latest research on our investigational cancer immunotherapy drug Imprime PGG,” said Jeremy Graff, Ph.D., Senior Vice ...
The clinical trial, KEYNOTE-046, is the first in human research of the firm's lead Lm-LLO immunotherapy candidate for prostate cancer. It is the second ...
From cancer immunotherapy and therapeutic vaccines to vaccines for pandemic influenza, Ebola, HIV, TB and malaria, Maryland's leaders are driving ...
Although cancer immunotherapy can lead to durable outcomes, the percentage of patients who respond to this disruptive approach remains modest to ...
Drugs targeting immune checkpoint molecules such as CTLA-4, PD-1, and PD-L1 are being heralded as a breakthrough in oncology. However ...
A genetic analysis led by Dr. Erik Knudsen (left) and Dr. Agnieszka Witkiewicz suggests that most pancreatic cancers harbor genetic alterations that ...
UT Southwestern Researchers Lead Collaborative Charge to Uncover Genetic Diversity of ... - Newswise (press release)
A genetic analysis led by UT Southwestern Medical Center researchers suggests that most pancreatic cancers harbor genetic alterations that could be ...
Nearly 50,000 Americans will be diagnosed with pancreatic cancer this year, and more than 40,000 will die from the disease. Notable Americans it has ...
Entitled, 'A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer' this article and ...
MRI could be used to screen for pancreatic cancer in individuals at high risk for the disease, according to early results from a Swedish study, published ...
We note that Reolysin already enjoys orphan drug status for primary peritoneal, fallopian tube, ovarian and pancreatic cancer in the U.S. and for ...
WEDNESDAY, April 8, 2015 (HealthDay News) -- Pancreatic cancer remains a "silent killer" because it is typically discovered too late for treatment to ...
MRI Could Be Useful Pancreatic Cancer Screen for High-Risk - Monthly Prescribing Reference
MRI Could Be Useful Pancreatic Cancer Screen for High-Risk - Doctors Lounge
Pancreatic ductal adenocarcinoma (PDA) can arise from either pancreaticintraepithelial neoplasia (PanIN, which is likely to be derived from acinar ...
A Phase 2 trial evaluating the combination in pancreatic cancer, Study 202, showed a doubling in median PFS compared to Abraxane and ...
The company plans to evaluate PEGPH20 in patients suffering from metastatic pancreatic cancer. The study design will allow the company to seek ...
Malignant primary brain cancer and pancreatic cancer drugs are the most common candidates for orphan drug status. An orphan drug designation ...
Pancreatic cancer is a common and very aggressive cancer, and our group at the BC Cancer Agency and Pancreas Centre BC is focused on trying to ...
BERKELEY, CA (UroToday.com) - Men have 3-4 times higher incidence of bladder cancer (BC) than women. To explain this male predilection, we ...
Bladder cancer is diagnosed in approximately 400,000 people and causes 150,000 deaths worldwide each year [1]. The majority of urinary tract ...
Novel Biologic Agents for Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia--Part 1
Here we review monoclonal antibodies that have received FDA approval for the treatment of NHL and CLL in the last 5 years, as well as promising agents in development.
Here we review monoclonal antibodies that have received FDA approval for the treatment of NHL and CLL in the last 5 years, as well as promising agents in development.
Commentary
The Era of Immuno-Oncology: Are We There Yet?
The next few years hold great promise, as new agents emerge and others consolidate their place on our shelves. We will be forced to rethink strategies and redefine management as a new era of immuno-oncology dawns.
The next few years hold great promise, as new agents emerge and others consolidate their place on our shelves. We will be forced to rethink strategies and redefine management as a new era of immuno-oncology dawns.
A note from our sponsor
Oncology EHR Vendor Pricing Comparison
Oncology requires an EHR with a full complement of features such as tumor staging, data-intensive workflows, chemotherapy dosing and administration, and survivorship care; features that oftentimes are not available in a generic system. An independent consultant was commissioned to evaluate different Oncology focused EHR vendors, click here to see the results now.
Oncology requires an EHR with a full complement of features such as tumor staging, data-intensive workflows, chemotherapy dosing and administration, and survivorship care; features that oftentimes are not available in a generic system. An independent consultant was commissioned to evaluate different Oncology focused EHR vendors, click here to see the results now.
Science Daily Cancer News
The prospect of combining genomically targeted therapies with drugs that free the immune system to attack cancer suggests 'we are finally poised to deliver curative therapies to cancer patients,' researchers state in a new report that covers the strengths and weaknesses of the two forms of therapy and notes how their combination could be particularly potent.
New evidence contradicts prior beliefs about how the protein PTEN -- one of the most important of the body's tumor suppressors -- works. Specifically, a new study shows how it is recruited to particular locations in our cells where pro-growth signals need to be shut off. This work could help scientists design more effective drugs to counteract cancer's hallmark trait, uncontrolled cellular growth.
New findings on HuR, an 'oncoprotein,' hold promise for treating every type of cancer tested, including cancers of the colon, prostate, breast, brain, ovaries, pancreas and lung, scientists report, adding that the findings could lead to a new class of cancer drugs.
Axillary lymph node evaluation is performed frequently in women with ductal carcinoma in situ breast cancer, despite recommendations generally against such an assessment procedure in women with localized cancer undergoing breast-conserving surgery, according to a study.
Researchers have zeroed in on what makes cancer cells in melanoma so aggressive. They also succeeded in taming the effect in cell cultures. Melanoma, a type of skin cancer, is notoriously quick to metastasize and responds poorly to existing cancer treatments. In their study, the researchers report a significant step forward in the characterization and potential treatment of melanoma.
In non-small cell lung cancer the new angiokinase inhibitor has advantages in patients without brain metastases, but disadvantages in patients with brain metastases. In principle, at most an indication of an added benefit can be derived from the results of the only study included in the manufacturer dossier. As the analysis of the data shows, the advantages or disadvantages of nintedanib in combination with docetaxel primarily depend on whether patients already had brain metastases at the start of the study or not.
A leading gene candidate that has been the target of breast cancer drug development may not be as promising as initially thought, according to new research. Mutation in the gene PIK3CA is the second most prevalent gene mutation in breast cancer and is found in 20% of all breast cancers. This has led people to think these changes may be driving breast cancer. Yet these mutations are also known to be present in neoplastic lesions -pre-cancerous growths many of which are thought to be benign, that have not invaded the surrounding tissue, scientists say.
Most pancreatic cancers harbor genetic alterations that could be targeted by existing drugs, using their genetic features as a roadmap for treatment, a genetic analysis suggests. The findings support a precision approach to treating pancreatic cancer, the fourth most deadly cancer for both men and women.
Melanoma is an aggressive form of skin cancer that has been increasing in incidence in adults over the past 40 years. Although pediatric melanoma is rare (5-6 children per million), most studies indicate that incidence has been increasing. In a new study, researchers found that the incidence of pediatric melanoma in the United States actually has decreased from 2004-2010.
A new study represents the first time low temperature plasmas (LTPs) have been applied on cells grown directly from patient tissue samples. Taking both healthy prostate cells and prostate cancer tissue cells from a single patient, the study allowed for direct comparison of the effectiveness of the treatment. Scientists discovered that LTPs may be a potential option for treatment of patients with organ confined prostate cancer, and a viable, more cost-effective alternative to current radiotherapy and photodynamic therapy (PDT) treatments.
Tambahkan Komentar